Forearm mass - Large Biopsy 3-6 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Tissue biopsy of swellings.

₹666₹951

30% OFF

Forearm Mass - Large Biopsy (3-6 cm)

Why is it done?
- Tissue diagnosis of palpable forearm masses measuring 3-6 cm in diameter
- Differentiate between benign and malignant soft tissue lesions (lipomas, fibromas, sarcomas, etc.)
- Obtain definitive pathological diagnosis when imaging studies are inconclusive or suggestive of malignancy
- Determine tumor grade, type, and guide treatment planning (surgical excision, chemotherapy, radiation)
- Evaluate recurrent or persistent masses after previous treatment
- Perform procedure when masses are >3 cm or require sufficient tissue sampling for comprehensive pathological analysis
Normal Range
- Normal Result: No malignancy; benign tissue confirmed
- Negative Result: Benign pathology (lipoma, hemangioma, fibroma, ganglion cyst, neurofibroma)
- Positive Result: Malignancy identified (sarcoma, lymphoma, metastatic disease)
- Measurement: Mass size 3-6 cm (optimal range for large core or open biopsy technique)
- Interpretation: Results are qualitative (descriptive histopathology) rather than quantitative; expressed as specific tissue type, grade, and stage when applicable
Interpretation
- Benign Lesions: Lipoma (most common), hemangioma, schwannoma, neurofibroma, giant cell tumor, ganglion cyst; typically require only excision or observation
- Malignant Lesions: Synovial sarcoma, liposarcoma, fibrosarcoma, rhabdomyosarcoma; require multimodal therapy (surgery, chemotherapy, radiation per histological grade and stage)
- Atypical/Uncertain Results: May require repeat biopsy, wider surgical excision with margin analysis, or molecular/genetic testing for classification
- Grade Assignment (if malignant): Low (Grade I), Intermediate (Grade II), or High (Grade III) - determines prognosis and aggressiveness of treatment
- Factors Affecting Interpretation: Specimen adequacy, degree of necrosis, presence of inflammation, prior treatment effects, tumor location (superficial vs deep affects behavior), patient age and comorbidities
- Immunohistochemistry (IHC): Special stains and IHC panels often performed to confirm diagnosis, determine cell lineage, and predict response to targeted therapy
Associated Organs
- Primary Organ System: Musculoskeletal system (soft tissues of forearm: muscles, tendons, ligaments, nerves, blood vessels, subcutaneous fat, fascia)
- Anatomical Region: Forearm compartments (flexor and extensor compartments), including radius and ulna bones and surrounding tissues
- Associated Malignancies: Soft tissue sarcomas (liposarcoma, synovial sarcoma, fibrosarcoma, myxofibrosarcoma, rhabdomyosarcoma, clear cell sarcoma, angiosarcoma)
- Associated Benign Conditions: Lipoma, hemangioma, schwannoma, neurofibroma, giant cell tumor of tendon sheath, ganglion cyst, cystic lesions, inflammatory myositis
- Potential Complications: Infection, bleeding/hematoma, nerve damage (radial/ulnar/median nerve injury with paresthesia or motor deficit), vascular injury, tumor seeding along biopsy tract (rare), compartment syndrome, wound complications
- Systemic Implications: Malignant diagnosis may indicate need for staging studies (CT, MRI, PET) to assess metastatic disease and involvement of regional lymph nodes
Follow-up Tests
- Definitive Surgical Treatment: Wide surgical excision with adequate margins (1-2 cm for benign; 2-3 cm for malignant) and margin assessment
- Staging Studies (if malignant): CT chest/abdomen/pelvis, MRI of primary site, PET-CT scan, bone scan for high-grade sarcomas to assess metastatic disease
- Lymph Node Assessment: Regional lymph node ultrasound or contrast-enhanced imaging (especially for high-grade or aggressive tumors)
- Molecular/Genetic Testing: FISH, PCR, or genomic sequencing for specific translocations (e.g., t(X;18) in synovial sarcoma) to confirm diagnosis and guide targeted therapy
- Oncology Consultation: Multidisciplinary tumor board review for treatment planning (surgery, chemotherapy, radiation therapy)
- Surveillance Imaging: Follow-up MRI or ultrasound at 3, 6, and 12 months post-treatment; then annually for 5 years for benign lesions if followed conservatively; frequent monitoring for malignant cases per protocol
- Repeat Biopsy: If initial specimen is non-diagnostic, shows only necrosis, or findings are discordant with imaging
- Functional Assessment: Physical examination and nerve conduction studies if nerve involvement suspected
Fasting Required?
- Fasting: No (fasting not required for biopsy)
- Anesthesia: Local anesthesia typically used (may require light sedation or general anesthesia depending on mass location and patient preference); if sedation/general anesthesia planned, then NPO for 6-8 hours prior
- Medications to Avoid: Anticoagulants (warfarin, DOACs) - discontinue per protocol (typically 3-5 days prior); NSAIDs (ibuprofen, aspirin) - hold 7-10 days before procedure; antiplatelet agents (clopidogrel) - discontinue if possible; verify with provider
- Pre-procedure Instructions: Informed consent required; baseline coagulation studies (PT/INR, PTT) if on anticoagulation; clean forearm with antiseptic soap day before or morning of procedure
- Imaging: Ultrasound or CT guidance recommended for optimal needle placement and to avoid vital structures (nerves, vessels)
- Post-procedure Care: Apply pressure dressing for 2-4 hours; ice to reduce swelling; pain control with acetaminophen or local analgesics; elevate arm; monitor for bleeding, swelling, signs of infection; sutures removal in 7-14 days if applicable
- Activity Restrictions: Avoid strenuous activities, heavy lifting, and submersion of biopsy site in water for 7-10 days; resume normal activities as tolerated
- Results Timeline: Preliminary histology within 24-48 hours; final report with special stains and IHC within 5-7 business days

How our test process works!